Discussion
A German biopharmaceutical company says it intends to launch two mid-stage clinical trials next year to test its oral treatment candidate izicopan — a next-generation therapy that developer Inflarx says may offer an “improved safety profile” and “more convenient dosing” — in people with ANCA-associated vasculitis (AAV).